Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sevoflurane + propofol + remifentanil
- Development stage
- Phase 4
- Lead developer
- Sakarya University
- Modality
- Small Molecules
- Administration
- Inhalation, Intravenous
01
Overview
sevoflurane + propofol + remifentanil is a combination anesthetic regimen utilized in Combined Intravenous-Inhalational Anesthesia (CIVIA). This combination integrates the effects of an inhalational halogenated ether (sevoflurane), an intravenous sedative-hypnotic (propofol), and a potent, ultra-short-acting intravenous opioid analgesic (remifentanil). Sakarya University is evaluating this specific combination in observational clinical trials to validate the clinical applicability of the Equivalent Minimum Alveolar Concentration (eMAC) parameter, which aims to provide a unified measure of anesthetic depth for combined techniques. The regimen works synergistically: sevoflurane and propofol primarily act as positive allosteric modulators of GABA-A receptors to induce hypnosis and amnesia, while remifentanil provides rapid-onset, titratable analgesia through mu-opioid receptor agonism.
- Other names
- CIVIACombined Intravenous-Inhalational Anesthesia
02
Targets
GABRR (GABA-A receptor subunit rho)MOR (Mu opioid receptor)NMDAR (Glutamate receptor ionotropic, NMDA)GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)GRIN1 (NMDA receptor subunit 1)
Beyond the preview
Go deeper on sevoflurane + propofol + remifentanil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sevoflurane + propofol + remifentanil.